<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737800</url>
  </required_header>
  <id_info>
    <org_study_id>obgynivf</org_study_id>
    <nct_id>NCT02737800</nct_id>
  </id_info>
  <brief_title>Effect of Prolonged GnRh Agonists on Results of Intracytoplasmic Sperm Injection (ICSI ) in Endometrioma Patients</brief_title>
  <acronym>GnRh</acronym>
  <official_title>Effect of Prolonged GnRh Agonist Therapy on the Outcome of In-Vitro Fertilization&amp; Embryo Transfer in Endometrioma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators compare ICSI results for endometrioma patients with or without cyst aspiration
      if more than 5cm &amp;with or without GnRh agonists for all endometrioma patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group 1 consists of 30 patients of endometrioma more than 5cm subdivided into:

      Group 1A;Cyst aspiration followed by standard long protocol in 15 patients Group 1B;Cyst
      aspiration followed by GnRh suppression for 3 months then standard long protocol in 15
      patients

      Group 2 consists of 30 patients of endometrioma less than 5cm subdivided into :

      Group 2A;no intervention to the cyst. Standard long protocol Group 2B;GnRh suppression for 3
      months then standard long protocol
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with urine pregnancy test positive 2 weeks after embryo transfer</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Endometrioma</condition>
  <arm_group>
    <arm_group_label>1A endometrioma more than 5cm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endometrioma aspiration GnRh agonist :Decapeptyl 3.75mg intramuscular Standard long stimulation protocol &amp; ICSI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B endometrioma more than 5cm control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Endometrioma aspiration Standard long stimulation protocol &amp; ICSI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A endometrioma less than 5cm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Decapeptyl 3.75mg intramuscular Standard long stimulation protocol &amp; ICSI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B endometrioma less than 5cm control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Standard long stimulation protocol &amp; ICSI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endometrioma aspiration</intervention_name>
    <description>Transvaginal ultrasound guided aspiration</description>
    <arm_group_label>1A endometrioma more than 5cm</arm_group_label>
    <arm_group_label>1B endometrioma more than 5cm control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRh agonist ( Decapeptyl )</intervention_name>
    <description>3 monthly doses of Decapeptyl 7.5mg intramuscular</description>
    <arm_group_label>1A endometrioma more than 5cm</arm_group_label>
    <arm_group_label>2A endometrioma less than 5cm</arm_group_label>
    <other_name>Decapeptyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard long stimulation protocol</intervention_name>
    <description>Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size &amp;serum estradiol.</description>
    <arm_group_label>1A endometrioma more than 5cm</arm_group_label>
    <arm_group_label>1B endometrioma more than 5cm control</arm_group_label>
    <arm_group_label>2A endometrioma less than 5cm</arm_group_label>
    <arm_group_label>2B endometrioma less than 5cm control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  endometrioma patients

        Exclusion Criteria:

          -  Follicle stimulating hormone(FSH)10 or more

          -  hydrosalpinx

          -  GnRh suppression in the last 12 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>suzy abdelaziz, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasr El Aini Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>suzy abdelaziz, lecturer</last_name>
    <phone>01003726195</phone>
    <email>suzyabdelaziz92@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasrelaini Hospital</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>suzy abdelaziz, lecturer</last_name>
      <phone>01003726195</phone>
      <email>suzyabdelaziz92@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>suzy abdelaziz Abdelhamid</investigator_full_name>
    <investigator_title>lecturer of obgyn.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

